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ABSTRACT 
Neuronal or axonal ion channel function can be impaired or altered in a number 
of disorders, such as acquired (autoantibody-mediated, toxic, and metabolic) 
and genetic channelopathies, and even neurodegenerative (motor neuron 
disease) or inflammatory diseases (multiple sclerosis, immune-mediated 
neuropathies). When specific channels are affected, axonal/neuronal excitability 
primarily alters according to original function of the corresponding channels. 
Separately, in the 1990’s, axonal excitability testing was developed to assess ion 
channel function, membrane potential, and passive membrane properties 
non-invasively in human subjects. Using this technique, numerous papers on 
altered axonal excitability in a variety of disorders have been published since 
2000. In a recent issue of Experimental Neurology, Park et al. demonstrated 
changes in peripheral axonal excitability in limbic encephalitis and acquired 
neuromyotonia with anti-voltage gated potassium channel antibodies. 
Unexpectedly, the results were not consistent with those caused by simple 
potassium channel blockade, suggesting multiple other factors contribute to 
altered axonal excitability. In contrast it was reported that patients with episodic 
ataxia type 1 (genetic channelopathy with mutation of Kv1.1 channel gene) show 
prominent excitability changes exactly compatible with fast potassium channel 
blockade. This commentary aims to highlight findings of this study in a broader 
context, and provides possible explanations for the discrepancy of patterns of 
axonal excitability changes in acquired and genetic potassium channelopathies.   
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Introduction 
Ion channelopathies are caused by dysfunction of channels due to hereditary or 
acquired disorders. Channelopathies affect almost all areas of neurological 
practice, including epilepsy, movement disorders, migraine, peripheral 
neuropathy, pain syndrome, and myopathy (Kullmann and Waxman, 2010). Over 
the past 2 decades, the concept of ion channelopathy has been significantly 
expanded. In addition to genetic channelopathies, neuronal or axonal ion 
channel function can be altered in a number of conditions, such as acquired 
(autoantibody-mediated, toxic, and metabolic) and even neurodegenerative 
(motor neuron disease) or inflammatory diseases (multiple sclerosis, 
immune-mediated neuropathies) (Kuwabara and Misawa, 2004, 2008; Kishnan 
et al., 2009).  
Furthermore, ionic conductances are largely affected by membrane 
potential and trans-axonal ionic concentration. For example, in chronic dialysis 
patients, axons are depolarized by hyperkalemia, resulting in increased axonal 
sodium and potassium conductances (Kiernan et al., 2002). Conversely under 
hypokalemia axonal membrane is hyperpolarized, and the ionic conductances 
are reduced (Kanai et al., 2002). Another example is diabetic neuropathy; under 
hyperglycemia, the activation of the polyol pathway leads to reduced Na+/K+ 
pump activity, and resulting intra-axonal sodium accumulation decreases sodium 
currents due to decreased trans-axonal sodium gradient. In this regard, uremic 
or diabetic neuropathy is a type of channelopathy (Kitano et al., 2004; Misawa et 
al., 2006a,b). Therefore ionic conductances and axonal excitability are 
dependent on the environmental conditions, as well as channel function itself.  
    Separately, an exciting development has been the identification of 
neurological disorders that are associated with specific antibodies to ion 
channels. The most common CNS syndrome associated with voltage-gated 
potassium channel (VGKC) antibodies is a form of limbic encephalitis (Irani et al., 
2010). Another example of anti-VGKC antibody-associated syndrome is 
acquired neuromyotonia, also termed as Isaacs syndrome and 
cramp-fasciculation syndrome, that is characterized by muscle cramp, 
myokymia, and fasciculations due to spontaneous repetitive firing of motor 
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axons. The motor axonal hyperexcitability are caused by suppression of fast 
potassium channels by anti-VGKC antibodies (Hart et al., 2002). 
    In a recent (or this) issue of Experimental Neurology, Park et al. reported 
changes in peripheral axonal excitability in patients with limbic encephalitis or 
acquired neuromyotonia, whose sera had high-titer of anti-VGKC antibodies 
(Park et al., 2014). Axonal excitability testing was performed at the wrist of the 
median nerve motor axons. Patients with limbic encephalitis demonstrated 
prominent abnormalities in peripheral axonal excitability during the acute phase, 
but the pattern of excitability property changes was not consistent with blockade 
of VGKC, and was possibly explained by reduced sodium currents because 
most of the patients had hyponatremia due to syndrome of inappropriate 
antidiuretic hormone secretion.  
They also showed that patients with acquired neuromyotonia demonstrated 
no significant changes at the site of stimulation. The total findings suggest that 
serum anti-VGKC antibodies did not affect excitability properties at the site of 
stimulation (tested site), largely because the antibodies cannot assess the tested 
motor axons by the blood-nerve barrier (see below). The findings indicate that 
not only the effects of anti-VGKC antibodies, but also a complex interaction of 
multiple factors should be taken into consideration in clinical situation, and 
therefore this study is interesting and of clinical significance.    
 
Nerve excitability testing 
Testing the excitability of axons can provide insights into the ionic mechanisms 
underlying the pathophysiology of axonal dysfunction in human. The technique 
of threshold tracking was developed in the 1990's, to non-invasively measures a 
number of axonal excitability indices, which depend on membrane potential and 
on the sodium and potassium conductances. By delivering conditioning stimulus, 
which alters membrane potential or activates specific ion channels, the current 
required to produce a target potential (threshold) will change. The techniques 
have been extensively applied to the study of the biophysical properties of 
human peripheral nerves in vivo and have provided important insights into 
axonal ion channel function in health and disease. This commentary focused on 
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assessment of potassium channel function (for the details on methodology and 
interpretations of nerve excitability testing, please refer to previous excellent 
review articles [Bostock et al., 1998; Krishnan et al., 2009]).   
    There are many types of potassium channels on axons (Reid et al., 1999), 
but it is convenient, for clinical purposes, to restrict discussion to two groups that 
are dependent on the membrane potential, those with fast kinetics (fast 
potassium channels) and those with slow kinetics (slow potassium channels). 
Fast potassium channels are located in the juxta-paranodal region, where they 
contribute to the resistance of the internodal membrane and limit the 
depolarizing afterpotential responsible for supernormality. Slow potassium 
channels have a density at the node 25 times that at the internode, but their 
kinetics are too slow to allow them to affect the action potential directly. They 
help to determine the resting membrane potential, contribute to accommodation 
to depolarizing stimuli, and are responsible for the late subnormality. In 
excitability testing, the S1d phase of threshold electrotonus and supernormality 
are limited by fast potassium conductance, and the S2 phase and subnormality 
are caused by slow potassium conductance. Therefore, patterns of combined 
findings of the threshold electrotonus and recovery cycle can provide information 
about fast and slow potassium conductances (Table 1; Figure 1).  
Briefly, in the threshold electrotonus studies, the membrane potential was 
altered by use of DC polarizing currents that were 40% of the unconditioned 
threshold. Depolarizing and hyperpolarizing currents were used, each lasting 
100ms, and their effects on the threshold current for the test motor responses 
were examined. The recovery cycle of axonal excitability after a single 
supramaximal stimulus was measured by delivering the test stimulus at different 
intervals after the conditioning stimulus. The interval between the conditioning 
and test stimulation were changed systematically from 2 to 200ms. When fast 
potassium channels are blocked, both the S1d phase and supernormality should 
increase (Bostock et al., 1998). 
 
Genetic potassium channelopathy (episodic ataxia type 1) and excitability 
Detailed nerve excitability findings in episodic ataxia type 1, a representative 
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genetic potassium channelopathy, have been reported (Tomlinson et al., 2010); 
episodic ataxia type 1 is a neuronal channelopathy caused by mutations in the 
KCNA1 gene encoding the fast potassium channel subunit Kv1.1. The disorder 
presents with brief episodes of cerebellar dysfunction and persistent 
neuromyotonia, and is associated with an increased incidence of epilepsy. The 
S1d phase in threshold electrotunus, and supernormality in the recovery cycle 
were prominently greater than those in normal controls. The findings exactly 
show loss of function of fast potassium channels. Using these two parameters, 
the patients with episodic ataxia type 1 and controls could be clearly separated 
into two non-overlapping groups. The authors concluded that nerve excitability 
testing is useful in diagnosis, since it can differentiate patients with episodic 
ataxia type 1 from normal controls with high sensitivity and specificity. 
    In a study by Park et al. (2014), the authors presumably expected the same 
findings, but results of actual recordings with the same techniques in patients 
with anti-VGKC antibodies were very different from those in patients with 
episodic ataxia type 1. The S1d phase of threshold electrotonus, and 
supernorality in the recovery cycle were smaller than those in normal controls, 
the opposite patterns to those of episodic ataxia type 1 (see Figure 1 in their 
paper). The findings indicate that changes in axonal excitability in patients with 
anti-VGKC antibodies are not caused by potassium channel blocking, and other 
factors should have contributed to the altered excitability. The unexpected 
results are considered to be due to multiple factors, and inaccessibility of the 
antibodies to the site (at the wrist portion of the median nerve) by the 
blood-nerve barrier is one of the factors.  
 
The blood-nerve barrier and autoantibodies 
Because of the blood-nerve barrier, large molecule substance such as 
immunoglobulin (antibodies) cannot access the nerve trunk. The internal 
microenvironment in the peripheral nerves is highly regulated. In humans, this 
regulation is facilitated by specialized tight junction-forming endoneurial 
microvascular endothelial cells. The endoneurial endothelial cells come in direct 
contact with circulating blood and, thus, can be considered the blood-nerve 
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barrier.  
However, the blood-nerve barrier is anatomically deficient in the distal nerve 
terminals, nerve roots, and dorsal root ganglia (Olsson, 1990). In 
immune-mediated neuropathies, such as Guillain-Barré syndrome and chronic 
inflammatory demyelinating neuropathy, it is established that the distal nerve 
terminals and nerve roots, where the blood–nerve barrier is deficient, are 
preferentially affected (Brown and Snow, 1994; Kuwabara et al., 2002), and the  
blood-nerve barrier partly determines the distribution of demyelinative lesions. 
Motor nerve conduction studies frequently show prolonged distal latencies and 
temporal dispersion of distally evoked compound muscle action potential, 
suggesting demyelination in the distal nerve segments in Guillain-Barré 
syndrome and chronic inflammatory demyelinating neuropathy.  
In anti-VGKC antibody-related disorders, the circulating antibodies can 
access the motor nerve terminals and roots, and fast potassium channels would 
be affected in these regions. Actually patients with acquired meuromyotonia in 
that study had motor nerve hyperexcitability evidenced by muscle cramp and 
fasciculations, and spontaneous motor unit activity on EMG examinations. Nerve 
excitability testing used in the study assess the excitability at the stimulus site 
(the wrist portion of the median nerve), where blood-nerve barrier functions, and 
therefore anti-VGKC antibodies did not affect the tested site (nerve trunk).     
 
Factor affecting axonal excitability 
As described in the Introduction, many factors can affect axonal ionic 
conductances and excitability. Ion channel dysfunction itself reasonably impairs 
the ionic currents, but many other factors, such as membrane potential, 
trans-axonal ionic gradient, exposure of channels by demyelination, and 
increased channels in axonal regeneration, can alter ionic conductances and 
thereby axonal excitability.  
   In a paper of Park et al. (2014), altered excitability properties in limbic 
encephalitis patients may be caused by hyponatremia due to syndrome of 
inappropriate antidiuretic hormone, and resulting reduced trans-axonal sodium 
gradient and reduced sodium currents. In patients with acquired neuromyotonia, 
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nerve excitability testing did not significantly affected by the lack of other factors 
influencing axonal excitability. In both cases, anti-VGKC antibodies did not affect 
the results. The results of this study are basically negative from a view of 
potassium channel blockade by the autoantibodies, but sufficiently educational, 
telling us that in clinical practice, the determinants of axonal excitability include 
many other factors, some of which are secondary or co-incident, and patients 
show a total effects of multiple factors.      
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Table 1. Axonal excitability indices and potassium channel conductance
Parameter Ion channel
Threshold electrotonus
S1d (Limited by) fast potassium channel
S2 Slow potassium channel
S3 Inward rectifying channel
Recovery cycle
Refractoriness Recovery from inactivation of sodium channel
Supernormality (Limited by) fast potassium channel
Late subnormality Slow potassium channel
S1d = peak of the slow phase in the depolarizing direction, see Figure 1.
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Figure legends 
Figure 1.  
Threshold electrotonus and recovery cycle measured in the median nerve at the 
wrist of a normal subject. A. Threshold electrotonus; changes in the threshold 
stimulus current for the target potential produced by subthreshold depolarizing or 
hyperpolarizing currents lasting 100 ms, with the intensity of the polarizing 
currents being 40% of the threshold. B. The recovery cycle of axonal excitability 
following a single supramaximal conditioning stimulus. At a short-conditioning 
test interval, the axons fall within the relatively refractory period, and the 
threshold current increases. At 3-4 ms, axons enter the supernormal period, and 
less current is required to activate them. Then axons enter the late subnormal 
period. The size of S1d and supernormality is limited by fast potassium currents, 
and therefore the size increase when potassium channels are impaired. 

